Bard boosts investment in percutaneous transluminal endomyocardial revascularisation (PTER) company:
This article was originally published in Clinica
Executive Summary
CR Bard has increased its investment in CorMedica, a US company developing systems for catheter-based percutaneous transluminal endomyocardial revascularisation (PTER). In March Bard secured exclusive worldwide distribution rights to eventual commercial products. Bard claims that PTER is a less-invasive technology that TMR and that CorMedica has a proprietary catheter tracking and navigation system.